Skip to content

Arvinas ARVN Short- term Investments

Short- term Investments at other companies

Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
Nuvation Bio logo
Nuvation BioNUVB
Enliven Therapeutics logo
Enliven TherapeuticsELVN
Erasca, Inc. logo
Erasca, Inc.ERAS
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's short- term investments?
Arvinas (ARVN) reported short- term investments of $527.6M in Q1 2026.
How has Arvinas's short- term investments changed year-over-year?
Arvinas's short- term investments decreased by 39.6% year-over-year, from $873.3M to $527.6M.
What is the long-term trend for Arvinas's short- term investments?
Over 5 years (2020 to 2025), Arvinas's short- term investments has grown at a 40.2% compound annual growth rate (CAGR), from $100.2M to $542.5M.